Aeterna Zentaris (AEZS) Posts Q4 Loss of $1.46/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results
March 29, 2016 5:00 PM EDTFourth quarter progress lays foundation for promising 2016
All amounts are in US Dollars
Fourth quarter key developments
Capital structure repaired Share consolidation successfully concluded Compliance with NASDAQ listing standards achieved $15.4 million of net capital obtained on favorable terms Product development advanced towards registration Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 clinical program received DSMB recommendation to continue to completion following review of the final interim efficacy and safety data; completion of trial scheduled for Q3 2016... More